Synonym
FAD-104; FAD104; FAD 104; FT-Adm; FTAdm; FT Adm; ME-2303; ME2303; ME 2303
IUPAC/Chemical Name
Heptanedioic acid, mono(2-(4-((2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethyl) ester, (2S-cis)-
InChi Key
PQMIPLRIRFVQJZ-QBYYVRQOSA-N
InChi Code
InChI=1S/C34H37FO15/c1-14-27(40)32(45)26(35)33(49-14)50-18-12-34(46,19(36)13-48-21(39)10-5-3-4-9-20(37)38)11-16-23(18)31(44)25-24(29(16)42)28(41)15-7-6-8-17(47-2)22(15)30(25)43/h6-8,14,18,26-27,32-33,40,42,44-46H,3-5,9-13H2,1-2H3,(H,37,38)/t14-,18-,26+,27+,32-,33-,34-/m0/s1
SMILES Code
COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@@H]5O[C@@H](C)[C@@H](O)[C@@H](O)[C@H]5F)c4c(O)c3C(=O)c12)C(=O)COC(=O)CCCCCC(=O)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
704.65
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1. Huxham IM, Barlow AL, Lewis AD, Plumb J, Mairs RJ, Gaze MN, Workman P. Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin-sensitive (A2780) and -resistant (A2780AD) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysis. Int J Cancer. 1994 Oct 1;59(1):94-102. doi: 10.1002/ijc.2910590118. PMID: 7927910.
2. Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. Cancer Res. 1989 Oct 15;49(20):5537-42. PMID: 2790778.
3. Iigo M, Hoshi A, Kadosawa H, Fujigaki M. Antitumor activity and metabolism of a new anthracycline-containing fluorine (ME2303) in Lewis lung carcinoma-bearing mice. Jpn J Cancer Res. 1991 Nov;82(11):1317-21. doi: 10.1111/j.1349-7006.1991.tb01798.x. PMID: 1752788; PMCID: PMC5918335.
4. Yoon EJ, Lee WI, Shim HJ, Lee SD, Kim WB, Yang J, Lee MG. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. Biopharm Drug Dispos. 1996 Jul;17(5):373-420. doi: 10.1002/(SICI)1099-081X(199607)17:5<373::AID-BDD373>3.0.CO;2-U. PMID: 8830976.
5. Omoto S, Kondo S, Fukatsu S, Takeuchi T, Umezawa K, Tsuchiya T, Umezawa S. Biological properties of ME2303 (FAD-104), a new anthracycline. Drugs Exp Clin Res. 1988;14(7):435-9. PMID: 3240704.
